Structure via PubChem · Public domain (PubChem)
apricoxib
Sign in to saveApricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID). It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer. It was also studied in clinical trials for non-small-cell lung cancer. Development was abandoned in 2015 due to poor clinical trial results.
Chemical data
- Formula
- C19H20N2O3S
- Molecular weight
- 356.4 g/mol
- IUPAC name
- 4-[2-(4-ethoxyphenyl)-4-methylpyrrol-1-yl]benzenesulfonamide
- SMILES
- CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
- InChIKey
- JTMITOKKUMVWRT-UHFFFAOYSA-N
- XLogP
- 3.2
- Polar surface area
- 82.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- pancreatic carcinoma, non-small cell lung carcinoma, breast cancer, multiple myeloma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 356.119
Show 5 more facts
- chemical formula
- C₁₉H₂₀N₂O₃S
- canonical SMILES
- CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
- Commons category
- Apricoxib
- subject has role
- COX-2 inhibitor
- physically interacts with
- Prostaglandin-endoperoxide synthase 2
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID). It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer. It was also studied in clinical trials for non-small-cell lung cancer. Development was abandoned in 2015 due to poor clinical trial results.
== References ==
Excerpted from Wikipedia’s “apricoxib” article, available under the CC BY-SA 4.0 licence.